BofA analyst Tazeen Ahmad initiated coverage of Taysha Gene Therapies (TSHA) with a Buy rating and $8 price target. Early data on TSHA-102 for Rett syndrome suggests treated patients can gain/regain developmental milestones, a differentiated result from current options, the analyst tells investors in a research note. The firm is modeling risk-adjusted peak sales for TSHA-102 in Rett syndrome of $995M by 2013, contributing $7/share, and thinks TSHA-102 will challenge Acadia’s (ACAD) Daybue, which has a market penetration of 35%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies initiated with a Buy at BofA
- Buy Rating for Taysha Gene Therapies: Favorable Study Design and High Responder Rate
- Craig-Hallum bullish on Neurogene, initiates with a Buy
- Promising Potential of Taysha Gene Therapies: Buy Rating Affirmed by Maury Raycroft
- Taysha Gene Therapies price target raised to $13 from $7 at Cantor Fitzgerald